Showing 1921-1930 of 5771 results for "".
- Neurolens Announces the Launch of the nMD2 Measurement Devicehttps://modernod.com/news/neurolens-announces-the-launch-of-the-nmd2-measurement-device/2479022/Neurolens has announced the launch of the neurolens Measurement Device, Gen 2 (nMD2), an objective and repeatable way to measure binocular vision, or more specifically, eye alignment. Employing over 10,000 data points per patient, the eye tracking system can identify eye misalignment as small as
- Gyroscope Therapeutics Announces $148 Million Raised in Series C Financinghttps://modernod.com/news/gyroscope-therapeutics-announces-148-million-raised-in-series-c-financing/2479018/Gyroscope Therapeutics announced it has raised $148.0 million (£107.8 million) in a Series C financing. Gyroscope plans to use proceeds from the financing to advance the clinical development of GT005,
- ProQR Announces Positive Results From Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trialshttps://modernod.com/news/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials/2479006/ProQR Therapeutics announced results from a planned analysis of its phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of v
- Eyenovia and Eversana Announce Partnership to Support the Potential Launch and Commercialization of MydCombi for Mydriasishttps://modernod.com/news/eyenovia-and-eversana-announce-partnership-to-support-the-potential-launch-and-commercialization-of-mydcombi-for-mydriasis/2479001/Eyenovia and Eversana announced a partnership to help commercialize MydCombi in the United States, if approved. This announcement follows the FDA’s recent acceptance of Eyenovia’s new drug application (NDA) for MydCombi, a fixed combination mydriatic (pupil dilation) agent. If approved, My
- MediPrint Ophthalmics Announces Completion of SIGHT-1 Phase 2a Clinical Studyhttps://modernod.com/news/mediprint-ophthalmics-announces-successful-completion-of-its-sight-1-phase-2a-clinical-study/2478983/MediPrint Ophthalmics announced the successful completion of the first study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatme
- NovaSight Announces First Pivotal Study for Lazy-Eye Digital Treatment Against Gold Standard Patchinghttps://modernod.com/news/novasight-announces-first-pivotal-study-for-lazy-eye-digital-treatment-against-gold-standard-patching/2478980/Israeli startup NovaSight has announced that it is running a large, pivotal multicenter randomized controlled trial to assess the safety and effectiveness of an eye-tracking-based treatment for amblyopia (lazy eye). This is the first pivotal study of its kind in children against the gold standard
- Kala Pharmaceuticals Announces Preferred Position for Eysuvis on Cignahttps://modernod.com/news/kala-pharmaceuticals-announces-preferred-position-for-eysuvis-on-cigna/2478977/Kala Pharmaceuticals announced that Cigna has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a preferred brand on its commercial formulary, effective May 15, 2021. “We are pleased to announce the addition of Eysuvis to Cigna’s preferred formulary, reflecting a signifi
- Visus Therapeutics Announces FDA Acceptance of IND to Proceed With Clinical Development of Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-fda-acceptance-of-ind-for-presbyopia-correcting-eye-drop/2478973/Visus Therapeutics announced that the FDA has accepted the company’s investigational new drug application (IND) to proceed with the clinical development program for Brimochol, the company’s lead investigational asset. Under this IND, Visus will initiate its planned phase 2 clinical trial in the U
- Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpointhttps://modernod.com/news/ocuphire-announces-mira-2-phase-3-registration-trial-for-the-reversal-of-mydriasis-meets-primary-endpoint/2478967/Ocuphire Pharma announced positive topline results in the MIRA-2 phase 3 registration trial investigating its product candidate Nyxol for reversal of pharmacologically induced mydriasis (dilation of pupil for eye exams). Nyxol is a proprietary, preservative-free, stable, investigational eye drop
- Bausch Health Announces CFO Succession Planhttps://modernod.com/news/bausch-health-announces-cfo-succession-plan/2478964/Bausch Health Companies announced that Paul S. Herendeen will be succeeded as Chief Financial Officer (CFO) by Sam Eldessouky, senior vice president, controller and chief accounting officer of Bausch Health. Mr. Herendeen is being appointed to the newly created role of Advisor to the chai